Novo Diabetes Drug Patent Is Obvious, Fed. Circ. Rules
While the appeals court reversed the lower court's finding finding that Novo's patent is unenforceable because of inequitable conduct, it found that Caraco had proven by clear and convincing evidence that it would have been obvious to combine two drugs to arrive at Novo's patented invention.
Already a subscriber? Click here to login